Peritonectomy and HIPEC by Professor Paul Sugarbaker

Slides:



Advertisements
Similar presentations
Is there a role for surgery in metastatic colorectal cancer?
Advertisements

Update on Ovarian Cancer
MDT I AARHUS Søren Laurberg Professor of Surgery Aarhus University Hospital Denmark.
Management of pseudomyxoma peritonei Rockson Wei Queen Mary Hospital Joint Hospital Surgical Grand Round 25 th July, 2009.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Rectal Cancer: A Complete Clinical Response…Now what?
 A 77-year-old comes to the ED with complaints of diarrhea, rectal pain and urgency for 3 days. His History is notable for Ischemic Heart disease, Hyperlipidemia,
Management of a rare type of Ca appendix Dr. Lam Tang Yu Tuen Mun Hospital Joint Hospital Surgical Grand Round.
Colon Cancer CS and HIPEC 2011
Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms Eng C 1, Blackham AU 2, Overman M 1, Fournier K 3, Royal R 3, Phillips.
Joint Hospital Surgical Grand Round 2/2/2013 Princess Margaret Hospital HM Li.
Laparoscopic Colon Surgery
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Silent but deadly – how to spot a sarcoma
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.
MESOTHELIOMA IS A RARE CANCER THAT OCCURS IN THE THIN LAYER OF TISSUE THAT COVERS THE MAJORITY OF YOUR INTERNAL ORGANS.
CASE STUDY: GI Surgery Cristel Moubarak – Dietetic Intern – 2014 Candidate Elena Tejedor – GI/ENT Surgery RD – Preceptor March 2014.
{ Upper Abdominal Debulking of Gynecologic Malignancies Shaun McKenzie, MD Assistant Professor of Surgery University of Kentucky.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms Eng C 1, Overman M 1, Fournier K 2, Royal R 2, Ohinata A 1,
Lymphadenectomy in Epithelial Ovarian Cancer
IRIA 67th Annual Conference
Present and Future of Hyperthermic intraperitoneal chemo (HIPEC) in Colorectal Peritoneal Metastases Dominique ELIAS Cancer Campus, Grand-Paris.
Gynecologic Malignancies Dr. David Edelmann Sharett Institute of Oncology Hadassah Medical Organization.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Padova, 30 maggio 2008 Carlo Riccardo Rossi Unità Melanoma e Sarcomi Clinica Chirurgica II - Università di Padova Ha uno spazio la chirurgia nella sarcomatosi.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.
Mesothelioma Nasty form of cancer Attributed to inhalation of asbestos fibers People who worked with or near asbestos typically at most risk.
Malignant Peritoneal Mesothelioma with Lung Metastasis.
ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
Lulic I, Miric M, Tomicic M, Palian M, Tomasevic B, Peric M
MESOTHELIOMA PROGNOSIS A mesothelioma prognosis reflects how certain factors may impact your life expectancy and affect your chances of recovery. The average.
SURVIVAL RATES Survival rates are another way to express the average cancer patient’s survival time with recent statistics. Because mesothelioma is so.
The role of chemotherapy in Borderline ovarian tumors Ines Vasconcelos, MD/PhD Oncology Center Kurfurstendamm, Berlin - DE.
PSEUDOMYXOMA PERITONEI Dr.Salahaldeen Abdulnabi Gastroenterology & Hepatology Center.
Metastatic Amelanotic Melanoma
For more details please visit our website:
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Chang-Yun Lu, Mao-Chih Hsieh
CRT 2012 Venous Disease.
The Uganda Cancer Institute Experience Walusansa Victoria.
What is it? How is it treated? What makes a person susceptible to it?
Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report Case Rep Oncol 2013;6:
A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Dr.Amit Gupta Associate Professor Dept. of Surgery
MCW Regional Cancer Therapy Program
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Peritoneal metastases can be cured
Radical appendectomy as an alternative to right colon resection in patients with epithelial appendiceal neoplasms  Santiago González-Moreno, Paul H. Sugarbaker 
Dr Monem Alshok Merjan Teaching Hospital GIT centre
CSS Clinical Trial Launched: January 2018
Dr Amit Gupta Associate Professor Dept of Surgery
Regional therapies for low-volume appendiceal carcinomas and pseudomyxoma peritonei
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,
PRESENTATOR: MD VƯƠNG NHẤT PHƯƠNG. HO CHI MINH CITY ONCOLOGY HOSPITAL
Mucinous Neoplasm of the Appendix and Pseudomyxoma Peritonei
Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,
CTCL: INNOVATIVE TREATMENTS GEMCITABINE
2018 National Mesothelioma Audit
Pulmonary Metastases in Pseudomyxoma Peritonei Syndrome
Survival After Surgical Resection of Stage IV Esophageal Cancer
Primary Small Cell Carcinoma of the Esophagus
NAACCR/IACR Combined Annual Conference 2019
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Presentation transcript:

Peritonectomy and HIPEC by Professor Paul Sugarbaker Materials for preview before his lecture, which will be hosted by Taiwan Joint Cancer Conference at 8:30- 9:30am, 7th May, 2017 at National Defense Medical College, Neihu, Taipei, Taiwan

Peritoneal Surface Malignancy

Peritoneal surface malignancy Peritoneal dissemination of abdominal malignancy (carcinomatosis) An extension of ovarian/salpingeal/app endiceal/colon/gastric malignancy and peritoneal mesothelioma a clinical course marked by bowel obstruction traditionally does not respond well to systemic therapy ©Ting-Chang Chang Dis Colon Rectum. 2012 Apr;55(4):407-15.

. There are oncology surgeons throughout many countries today using the techniques that Paul Sugarbaker, M.D., pioneered years ago. Paul Sugarbaker has carved an impressive career in Washington, D.C., serving as the director of the Peritoneal Surface Malignancy Program at the Washington Cancer Institute. He is considered one of the nation’s innovators and authorities on the treatment of peritoneal mesothelioma, a rare form of cancer that attacks the lining of the abdomen and is traced to asbestos exposure. He has also been involved in the treatment of other diseases, such as abdominal sarcomas, peritoneal carcinomatosis and pseudomyxoma peritonei. Sugarbaker is best known for his development of multi-modal approach to the treatment of different cancers. His use of cytoreductive surgery, coupled with intraperitoneal chemotherapy, has become widespread because of the success he experienced.

Peritoneal surface malignancy cytoreductive surgery with hyperthermic intraperitoneal chemotherapy Complete cytoreductive surgery and HIPEC showed a median survival of 33 months, comparing a median survival of 5.2-7 months in the era of fluorouracil Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis showed a media overall survival of 9.8 years Transl Gastrointest Cancer 2013;2(2):54-74 Dis Colon Rectum. 2012 Apr;55(4):407-15.

Distribution of PSM origin varied in hospitals

Dr. Paul Sugarbaker Sugarbaker procedure http://health.heraldtribune.com/2012/12/31/last-hope-surgery/ Sugarbaker procedure